Chronic kidney disease treatment Market By Treatment (Drugs, Dialysis), By End User (Hospital, Dialysis Center, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "Chronic kidney disease treatment Market," The chronic kidney disease treatment market was valued at $32 billion in 2022, and is estimated to reach $47.9 billion by 2032, growing at a CAGR of 4% from 2023 to 2032.

Chronic kidney disease treatment Market - IMG1

Chronic Kidney Disease (CKD) treatment refers to a range of medical interventions and strategies aimed at managing and slowing the progression of kidney damage and its associated complications. CKD is a progressive condition where the kidneys gradually lose their ability to filter waste products and excess fluids from the blood. The goals of CKD treatment include preserving kidney function, controlling symptoms, preventing or managing complications, and improving the overall quality of life for individuals with CKD.

Treatment approaches may include lifestyle modifications (such as dietary changes and regular physical activity), medications to control blood pressure and manage underlying conditions, interventions to address complications like anemia or bone disease, and in advanced stages, renal replacement therapies such as dialysis or kidney transplantation. The treatment plan is tailored to the individual's stage of CKD, underlying causes, comorbidities, and overall health status. Regular monitoring, close collaboration with healthcare providers, and adherence to the treatment plan are essential for optimizing outcomes and maintaining kidney health in individuals with CKD.

The increasing prevalence of CKD is a significant driver of the CKD treatment market. The global burden of CKD has been steadily rising due to various factors, including the aging population, the growing prevalence of risk factors such as diabetes and hypertension, and improved awareness and diagnosis. For instance, the aging population is a major contributing factor to the increasing prevalence of CKD. As people age, the risk of developing CKD tends to increase. According to the World Health Organization (WHO) in 2022, the global population aged 60 and above is expected to reach 2 billion by 2050, with a significant impact on the prevalence of age-related diseases, including CKD.

Furthermore, the rising incidence of risk factors like diabetes and hypertension has fueled the CKD epidemic. Diabetes, in particular, is a leading cause of CKD. The International Diabetes Federation in 2021, estimates that approximately 537 million adults were living with diabetes, and this number is projected to rise to 643 million by 2030 and 783 million by 2045. Thus, the prevailing cases, that directly translate to a higher risk of CKD development are anticipated to drive the market growth.

In addition, increase in alcohol consumption, rise in the number of diagnostic tests for kidney diseases, surge in obese population, rise in R&D activities for launch of novel drugs and improvement in the existing drugs, and emerging technology in developing economies are positively impacting the growth of the chronic kidney disease treatment market.

However, factors that hinder the market growth include the high cost of treatment for chronic kidney disease. Further, limited access to healthcare and inadequate healthcare infrastructure in certain regions can hinder the timely diagnosis and management of CKD. Thus, the aforementioned factors negatively impact market growth.

Moreover, the rise in the number of approvals from government regulatory agencies is creating lucrative opportunities for the CKD treatment market. For instance, in September 2022, AstraZeneca, a global leading life science company, received approval in China for Forxiga, to reduce the risk of sustained estimated glomerular filtration rate ((eGFR)) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression with and without type-2 diabetes (T2D). In addition, the increase in investment in R&D activities increases the demand for efficient treatments, thereby providing lucrative opportunities for market growth.

The chronic kidney disease treatment market is segmented on the basis of treatment, end user, and region. On the basis of treatment, the market is classified into drugs and dialysis. The drugs is further categories into ACE Inhibitors, Erythropoietic Stimulating agents, Diuretics, and Other (phosphate binder, beta blockers, calcium channel blockers) and the dialiysis is further categorised into equipment and consumables. As per end user the market is segmented into Hospitals , Dialysis Centers and others (homecare and research and academic institutes). Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global chronic kidney disease treatment market are AstraZeneca plc, Pfizer Inc. Johnson & Johnson, F. Hoffmann-La Roche Ltd., Baxter International Inc., Becton, Dickinson and Company, B. Braun SE, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Fresenius SE and Co. KGaA. Key players operating in the market have adopted product approval, acquisition, and product launch as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic kidney disease treatment market analysis from 2022 to 2032 to identify the prevailing chronic kidney disease treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the chronic kidney disease treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global chronic kidney disease treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By End User

Hospital
Dialysis Center
Others

By Treatment

Drugs
- Type
- Erythropoietic Stimulating agents
- Ace Inhibitors
- Diuretics
- Others
Dialysis
- Type
- Equipment
- Consumables

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Pfizer Inc.
Becton, Dickinson and Company
F. Hoffmann-La Roche Ltd.
AstraZeneca plc
B. Braun SE
AbbVie Inc.
Fresenius SE and Co. KGaA
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.
Baxter International Inc.

Product Code: A107121

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Technological advancement in chronic kidney disease treatment
  - 3.4.1.2. Increase in prevalence of chronic kidney disease (CKD)

3.4.2. Restraints
- 3.4.2.1. High cost of CKD treatment

3.4.3. Opportunities
- 3.4.3.1. Growth opportunities in emerging markets

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Drugs
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.2.4. Drugs Chronic kidney disease treatment Market by Type
4.3. Dialysis
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.3.4. Dialysis Chronic kidney disease treatment Market by Type

CHAPTER 5: CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Hospital
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Dialysis Center
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY REGION

6.1. Overview
- 6.1.1. Market size and forecast By Region
6.2. North America
- 6.2.1. Key trends and opportunities
- 6.2.2. Market size and forecast, by Treatment
- 6.2.3. Market size and forecast, by End User
- 6.2.4. Market size and forecast, by country
  - 6.2.4.1. U.S.
  - 6.2.4.1.1. Key market trends, growth factors and opportunities
  - 6.2.4.1.2. Market size and forecast, by Treatment
  - 6.2.4.1.3. Market size and forecast, by End User
  - 6.2.4.2. Canada
  - 6.2.4.2.1. Key market trends, growth factors and opportunities
  - 6.2.4.2.2. Market size and forecast, by Treatment
  - 6.2.4.2.3. Market size and forecast, by End User
  - 6.2.4.3. Mexico
  - 6.2.4.3.1. Key market trends, growth factors and opportunities
  - 6.2.4.3.2. Market size and forecast, by Treatment
  - 6.2.4.3.3. Market size and forecast, by End User
6.3. Europe
- 6.3.1. Key trends and opportunities
- 6.3.2. Market size and forecast, by Treatment
- 6.3.3. Market size and forecast, by End User
- 6.3.4. Market size and forecast, by country
  - 6.3.4.1. Germany
  - 6.3.4.1.1. Key market trends, growth factors and opportunities
  - 6.3.4.1.2. Market size and forecast, by Treatment
  - 6.3.4.1.3. Market size and forecast, by End User
  - 6.3.4.2. France
  - 6.3.4.2.1. Key market trends, growth factors and opportunities
  - 6.3.4.2.2. Market size and forecast, by Treatment
  - 6.3.4.2.3. Market size and forecast, by End User
  - 6.3.4.3. UK
  - 6.3.4.3.1. Key market trends, growth factors and opportunities
  - 6.3.4.3.2. Market size and forecast, by Treatment
  - 6.3.4.3.3. Market size and forecast, by End User
  - 6.3.4.4. Italy
  - 6.3.4.4.1. Key market trends, growth factors and opportunities
  - 6.3.4.4.2. Market size and forecast, by Treatment
  - 6.3.4.4.3. Market size and forecast, by End User
  - 6.3.4.5. Spain
  - 6.3.4.5.1. Key market trends, growth factors and opportunities
  - 6.3.4.5.2. Market size and forecast, by Treatment
  - 6.3.4.5.3. Market size and forecast, by End User
  - 6.3.4.6. Rest of Europe
  - 6.3.4.6.1. Key market trends, growth factors and opportunities
  - 6.3.4.6.2. Market size and forecast, by Treatment
  - 6.3.4.6.3. Market size and forecast, by End User
6.4. Asia-Pacific
- 6.4.1. Key trends and opportunities
- 6.4.2. Market size and forecast, by Treatment
- 6.4.3. Market size and forecast, by End User
- 6.4.4. Market size and forecast, by country
  - 6.4.4.1. Japan
  - 6.4.4.1.1. Key market trends, growth factors and opportunities
  - 6.4.4.1.2. Market size and forecast, by Treatment
  - 6.4.4.1.3. Market size and forecast, by End User
  - 6.4.4.2. China
  - 6.4.4.2.1. Key market trends, growth factors and opportunities
  - 6.4.4.2.2. Market size and forecast, by Treatment
  - 6.4.4.2.3. Market size and forecast, by End User
  - 6.4.4.3. Australia
  - 6.4.4.3.1. Key market trends, growth factors and opportunities
  - 6.4.4.3.2. Market size and forecast, by Treatment
  - 6.4.4.3.3. Market size and forecast, by End User
  - 6.4.4.4. India
  - 6.4.4.4.1. Key market trends, growth factors and opportunities
  - 6.4.4.4.2. Market size and forecast, by Treatment
  - 6.4.4.4.3. Market size and forecast, by End User
  - 6.4.4.5. South Korea
  - 6.4.4.5.1. Key market trends, growth factors and opportunities
  - 6.4.4.5.2. Market size and forecast, by Treatment
  - 6.4.4.5.3. Market size and forecast, by End User
  - 6.4.4.6. Rest of Asia-Pacific
  - 6.4.4.6.1. Key market trends, growth factors and opportunities
  - 6.4.4.6.2. Market size and forecast, by Treatment
  - 6.4.4.6.3. Market size and forecast, by End User
6.5. LAMEA
- 6.5.1. Key trends and opportunities
- 6.5.2. Market size and forecast, by Treatment
- 6.5.3. Market size and forecast, by End User
- 6.5.4. Market size and forecast, by country
  - 6.5.4.1. Brazil
  - 6.5.4.1.1. Key market trends, growth factors and opportunities
  - 6.5.4.1.2. Market size and forecast, by Treatment
  - 6.5.4.1.3. Market size and forecast, by End User
  - 6.5.4.2. Saudi Arabia
  - 6.5.4.2.1. Key market trends, growth factors and opportunities
  - 6.5.4.2.2. Market size and forecast, by Treatment
  - 6.5.4.2.3. Market size and forecast, by End User
  - 6.5.4.3. South Africa
  - 6.5.4.3.1. Key market trends, growth factors and opportunities
  - 6.5.4.3.2. Market size and forecast, by Treatment
  - 6.5.4.3.3. Market size and forecast, by End User
  - 6.5.4.4. Rest of LAMEA
  - 6.5.4.4.1. Key market trends, growth factors and opportunities
  - 6.5.4.4.2. Market size and forecast, by Treatment
  - 6.5.4.4.3. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

8.1. AstraZeneca plc
- 8.1.1. Company overview
- 8.1.2. Key Executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
- 8.1.6. Business performance
- 8.1.7. Key strategic moves and developments
8.2. Pfizer Inc.
- 8.2.1. Company overview
- 8.2.2. Key Executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.2.6. Business performance
8.3. Johnson & Johnson
- 8.3.1. Company overview
- 8.3.2. Key Executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
- 8.3.6. Business performance
8.4. F. Hoffmann-La Roche Ltd.
- 8.4.1. Company overview
- 8.4.2. Key Executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
8.5. Baxter International Inc.
- 8.5.1. Company overview
- 8.5.2. Key Executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
- 8.5.6. Business performance
8.6. Becton, Dickinson and Company
- 8.6.1. Company overview
- 8.6.2. Key Executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Business performance
8.7. B. Braun SE
- 8.7.1. Company overview
- 8.7.2. Key Executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
- 8.7.6. Business performance
- 8.7.7. Key strategic moves and developments
8.8. AbbVie Inc.
- 8.8.1. Company overview
- 8.8.2. Key Executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
8.9. Teva Pharmaceutical Industries Ltd.
- 8.9.1. Company overview
- 8.9.2. Key Executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
- 8.9.6. Business performance
8.10. Fresenius SE and Co. KGaA
- 8.10.1. Company overview
- 8.10.2. Key Executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio
- 8.10.6. Business performance
- 8.10.7. Key strategic moves and developments